In response to the requests received by patients living with Spinal Muscular Atrophy (SMA), Biogen Canada would like to provide this latest progress regarding coverage of SPINRAZA™ (nusinersen) in the province of Saskatchewan.

Biogen Canada is delighted to inform you that on April 12, 2019, the Government of Saskatchewan informed treating physicians in their province that patients living with Spinal Muscular Atrophy (SMA) have access to SPINRAZA™. The Saskatchewan Ministry of Health has made the decision to expand coverage of SPINRAZA™ to include the following, in addition to existing Type I patients:

Patients who are pre-symptomatic with two or three copies of the SMN2 gene;

Patients up to age 18, with symptom onset after six months of age and who have never achieved the ability to walk independently;

Patients that may have achieved the ability to walk independently (type III) as well as type II and type III patients over the age of 18 are encouraged to talk to their treating physician to apply for a case by case coverage.

STATEMENT REGARDING PHONE SOLICITATIONS Muscular Dystrophy Canada does not use telemarketing services. Several years ago, the Canadian Fire Fighter Curling Association (CFFCA) retained a telemarketing company to assist in fundraising …READ MORE

MDC pleased to provide CADTH with a patient submission from our generalized Myasthenia Gravis (GMG) community in support of Soliris. MDC remains committed to ensuring that neuromuscular clients have access …READ MORE

Toronto, Ontario – Muscular Dystrophy Canada commends the Government of Canada for committing $35 million, in its 2019 budget, to develop a Canadian Drug Agency to oversee the development of …READ MORE